Evaluation of an extended-release formulation of ceftiofur crystalline-free acid in koi (Cyprinus carpio)

C. Grosset, E. S. Weber, R. Gehring, David Guzman, L. A. Campbell, C. Enz, J. M. Groff, Lisa A Tell

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The use of an extended release ceftiofur crystalline-free acid formulation (CCFA, Excede For Swine®, Pfizer Animal Health) in koi was evaluated after administration of single intramuscular (i.m.) or intracoelomic (i.c.) doses. Twenty koi were divided randomly into a control group and four treatment groups (20 mg/kg i.m., 60 mg/kg i.m., 30 mg/kg i.c., and 60 mg/kg i.c.). Serum ceftiofur-free acid equivalents (CFAE) concentrations were quantified. The pharmacokinetic data were analyzed using a nonlinear mixed-effects approach. Following a CCFA injection of 60 mg/kg i.m., time durations that serum CFAE concentrations were above the target concentration of 4 μg/mL ranged from 0.4 to 2.5 weeks in 3 of 4 fish, while serum CFAE concentrations remained below 4 μg/mL for lower doses evaluated. Substantial inter-individual variations and intra-individual fluctuations of CFAE concentrations were observed for all treatment groups. Histological findings following euthanasia included aseptic granulomatous reactions, but no systemic adverse effects were detected. Given the unpredictable time vs. CFAE concentration profiles for treated koi, the authors would not recommend this product for therapeutic use in koi at this time. Further research would be necessary to correlate serum and tissue concentrations and to better establish MIC data for Aeromonas spp. isolated from naturally infected koi.

Original languageEnglish (US)
Pages (from-to)606-615
Number of pages10
JournalJournal of Veterinary Pharmacology and Therapeutics
Volume38
Issue number6
DOIs
StatePublished - Dec 1 2015

Fingerprint

koi
ceftiofur
Carps
Cyprinus carpio
Acids
acids
Serum
Aeromonas
Euthanasia
Therapeutic Uses
euthanasia
dosage
animal health
pharmacokinetics
Fishes
Swine
Pharmacokinetics
adverse effects
injection
therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • veterinary(all)

Cite this

Evaluation of an extended-release formulation of ceftiofur crystalline-free acid in koi (Cyprinus carpio). / Grosset, C.; Weber, E. S.; Gehring, R.; Guzman, David; Campbell, L. A.; Enz, C.; Groff, J. M.; Tell, Lisa A.

In: Journal of Veterinary Pharmacology and Therapeutics, Vol. 38, No. 6, 01.12.2015, p. 606-615.

Research output: Contribution to journalArticle

Grosset, C. ; Weber, E. S. ; Gehring, R. ; Guzman, David ; Campbell, L. A. ; Enz, C. ; Groff, J. M. ; Tell, Lisa A. / Evaluation of an extended-release formulation of ceftiofur crystalline-free acid in koi (Cyprinus carpio). In: Journal of Veterinary Pharmacology and Therapeutics. 2015 ; Vol. 38, No. 6. pp. 606-615.
@article{9ea2775728c1479f9b12328084a9f1d1,
title = "Evaluation of an extended-release formulation of ceftiofur crystalline-free acid in koi (Cyprinus carpio)",
abstract = "The use of an extended release ceftiofur crystalline-free acid formulation (CCFA, Excede For Swine{\circledR}, Pfizer Animal Health) in koi was evaluated after administration of single intramuscular (i.m.) or intracoelomic (i.c.) doses. Twenty koi were divided randomly into a control group and four treatment groups (20 mg/kg i.m., 60 mg/kg i.m., 30 mg/kg i.c., and 60 mg/kg i.c.). Serum ceftiofur-free acid equivalents (CFAE) concentrations were quantified. The pharmacokinetic data were analyzed using a nonlinear mixed-effects approach. Following a CCFA injection of 60 mg/kg i.m., time durations that serum CFAE concentrations were above the target concentration of 4 μg/mL ranged from 0.4 to 2.5 weeks in 3 of 4 fish, while serum CFAE concentrations remained below 4 μg/mL for lower doses evaluated. Substantial inter-individual variations and intra-individual fluctuations of CFAE concentrations were observed for all treatment groups. Histological findings following euthanasia included aseptic granulomatous reactions, but no systemic adverse effects were detected. Given the unpredictable time vs. CFAE concentration profiles for treated koi, the authors would not recommend this product for therapeutic use in koi at this time. Further research would be necessary to correlate serum and tissue concentrations and to better establish MIC data for Aeromonas spp. isolated from naturally infected koi.",
author = "C. Grosset and Weber, {E. S.} and R. Gehring and David Guzman and Campbell, {L. A.} and C. Enz and Groff, {J. M.} and Tell, {Lisa A}",
year = "2015",
month = "12",
day = "1",
doi = "10.1111/jvp.12227",
language = "English (US)",
volume = "38",
pages = "606--615",
journal = "Journal of Veterinary Pharmacology and Therapeutics",
issn = "0140-7783",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Evaluation of an extended-release formulation of ceftiofur crystalline-free acid in koi (Cyprinus carpio)

AU - Grosset, C.

AU - Weber, E. S.

AU - Gehring, R.

AU - Guzman, David

AU - Campbell, L. A.

AU - Enz, C.

AU - Groff, J. M.

AU - Tell, Lisa A

PY - 2015/12/1

Y1 - 2015/12/1

N2 - The use of an extended release ceftiofur crystalline-free acid formulation (CCFA, Excede For Swine®, Pfizer Animal Health) in koi was evaluated after administration of single intramuscular (i.m.) or intracoelomic (i.c.) doses. Twenty koi were divided randomly into a control group and four treatment groups (20 mg/kg i.m., 60 mg/kg i.m., 30 mg/kg i.c., and 60 mg/kg i.c.). Serum ceftiofur-free acid equivalents (CFAE) concentrations were quantified. The pharmacokinetic data were analyzed using a nonlinear mixed-effects approach. Following a CCFA injection of 60 mg/kg i.m., time durations that serum CFAE concentrations were above the target concentration of 4 μg/mL ranged from 0.4 to 2.5 weeks in 3 of 4 fish, while serum CFAE concentrations remained below 4 μg/mL for lower doses evaluated. Substantial inter-individual variations and intra-individual fluctuations of CFAE concentrations were observed for all treatment groups. Histological findings following euthanasia included aseptic granulomatous reactions, but no systemic adverse effects were detected. Given the unpredictable time vs. CFAE concentration profiles for treated koi, the authors would not recommend this product for therapeutic use in koi at this time. Further research would be necessary to correlate serum and tissue concentrations and to better establish MIC data for Aeromonas spp. isolated from naturally infected koi.

AB - The use of an extended release ceftiofur crystalline-free acid formulation (CCFA, Excede For Swine®, Pfizer Animal Health) in koi was evaluated after administration of single intramuscular (i.m.) or intracoelomic (i.c.) doses. Twenty koi were divided randomly into a control group and four treatment groups (20 mg/kg i.m., 60 mg/kg i.m., 30 mg/kg i.c., and 60 mg/kg i.c.). Serum ceftiofur-free acid equivalents (CFAE) concentrations were quantified. The pharmacokinetic data were analyzed using a nonlinear mixed-effects approach. Following a CCFA injection of 60 mg/kg i.m., time durations that serum CFAE concentrations were above the target concentration of 4 μg/mL ranged from 0.4 to 2.5 weeks in 3 of 4 fish, while serum CFAE concentrations remained below 4 μg/mL for lower doses evaluated. Substantial inter-individual variations and intra-individual fluctuations of CFAE concentrations were observed for all treatment groups. Histological findings following euthanasia included aseptic granulomatous reactions, but no systemic adverse effects were detected. Given the unpredictable time vs. CFAE concentration profiles for treated koi, the authors would not recommend this product for therapeutic use in koi at this time. Further research would be necessary to correlate serum and tissue concentrations and to better establish MIC data for Aeromonas spp. isolated from naturally infected koi.

UR - http://www.scopus.com/inward/record.url?scp=84945450584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945450584&partnerID=8YFLogxK

U2 - 10.1111/jvp.12227

DO - 10.1111/jvp.12227

M3 - Article

C2 - 25876672

AN - SCOPUS:84945450584

VL - 38

SP - 606

EP - 615

JO - Journal of Veterinary Pharmacology and Therapeutics

JF - Journal of Veterinary Pharmacology and Therapeutics

SN - 0140-7783

IS - 6

ER -